IP Library Granted Patent US 8,329,905
Granted Patent B2
US 8,329,905 · App. 12/701,174 · Granted Dec 11, 2012

Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,329,905
App. No.
12/701,174
Granted
Dec 11, 2012
Kind
B2
Abstract

This application discloses a novel process for the preparation of phosphonate esters useful as intermediates in the preparation of himbacine analogs, themselves useful as thrombin receptor antagonists. The chemistry taught herein can be exemplified by the following scheme: wherein R 9 is selected from alkyl, aryl heteroaryl and arylalkyl groups having 1 to 10 carbon atoms, and R 11 is selected independently for each occurrence from alkyl, aryl heteroaryl and arylalkyl groups having 1 to 10 carbon atoms and hydrogen, X 2 is Cl, Br, or I; X 3 is selected from Cl and Br; and PdL n is a supported palladium metal catalyst or a soluble heterogeneous palladium catalyst. The L-derivatizing reagent is a moiety which converts the alcohol functional group of compound 137D to any leaving group which can be displaced by a triorgano-phosphite phosphonating agent.

Claims (45)

1. A process for making a compound of the structure of compound 116

wherein R 9 is separately selected for each occurrence from alkyl, aryl, heteroaryl, and arylalkyl groups having 1 to 10 carbon atoms, the process comprising:

reacting a hydrochloride salt compound having the structure of compound 139, where R 9 is as defined above,

with 3-fluorophenylboronic acid in the presence of a palladium catalyst.

2. The process of claim 1 wherein compound 139 is provided by

(a) reacting the hydrochloride salt of the structure of compound 137

with a phosphite compound of the structure of Formula A

wherein R 9 is separately selected for each occurrence from alkyl, aryl, heteroaryl, and arylalkyl groups having 1 to 10 carbon atoms; and

(b) treating the reaction product from step “a” with HCl to obtain compound 139.

3. The process of claim 2 wherein the phosphite compound used in step “a” is a trialkyl phosphite.

4. The process of claim 3 wherein the trialkyl phosphite used in step “a” is triethyl phosphite.

5. The process of claim 1 wherein said palladium catalyst is palladium metal supported on carbon black or a soluble palladium catalyst.

6. The process of claim 2 wherein said palladium catalyst is palladium metal supported on carbon black or a soluble palladium catalyst.

7. The process of claim 3 wherein said palladium catalyst is palladium metal supported on carbon black or a soluble palladium catalyst.

8. The process of claim 4 wherein said palladium catalyst is palladium metal supported on carbon black or a soluble palladium catalyst.

9. The process claim 2 further comprising after the “treating” step “b”, the step of precipitating the phosphonate hydrochloride formed in step “b” by adding an antisolvent to the reaction mixture containing the phosphonate hydrochloride compound of structure 139.

10. The process claim 3 further comprising after the “treating” step “b”, the step of precipitating the phosphonate hydrochloride formed in step “b” by adding an antisolvent to the reaction mixture containing the phosphonate hydrochloride compound of structure 139.

11. The process claim 4 further comprising after the “treating” step “b”, the step of precipitating the phosphonate hydrochloride formed in step “b” by adding an antisolvent to the reaction mixture containing the phosphonate hydrochloride compound of structure 139.

12. The process of claim 6 further comprising, after the “treating” step “b”, the step of precipitating the phosphonate hydrochloride formed in step “b” by adding an antisolvent to the reaction mixture containing the phosphonate hydrochloride compound of structure 139.

13. A process for making a compound of the structure of compound 116

wherein R 9 is separately selected for each occurrence from alkyl, aryl, heteroaryl, and arylalkyl groups having 1 to 10 carbon atoms, the process comprising;

(a) reacting (5-halo-pyridin-2-yl)-methanol of the Formula 137A

where X 2 is selected independently from Cl, Br, or I;

with an X 1 halogenating agent, to produce a compound of the formula of compound 137,

where X 1 is the same for each occurrence and is selected from Cl or Br and X 2 is as defined above;

(b) reacting compound 137 with a phosphite compound of the structure of Formula A,

wherein R 9 is selected from alkyl, aryl, heteroaryl, and arylalkyl groups having 1 to 10 carbon atoms, to produce compound 138,

wherein R 9 is as defined above;

(c) treating compound 138 with HX 3 , where X 3 is selected from Cl and Br, to precipitate the corresponding hydrohalide salt of Formula 138A,

wherein R 9 is as defined above; and

(d) reacting the hydrohalide salt from step “c” with a 3-fluorophenylboronate compound of the structure of Formula B

wherein R 11 is selected independently for each occurrence from alkyl, aryl heteroaryl and arylalkyl groups having 1 to 10 carbon atoms and hydrogen, optionally in the presence of a palladium catalyst to produce compound 116.

14. A process for making a compound of the structure of compound 116

wherein R 9 is separately selected for each occurrence from alkyl, aryl, heteroaryl, and arylalkyl groups having 1 to 10 carbon atoms, the process comprising:

(a) reacting (5-halo-pyridin-2-yl)-methanol of the Formula 137A

where X 2 is selected independently from Cl, Br, or I, with an X 1 halogenating agent, to produce a compound of the formula of compound 137,

where X 1 is the same for each occurrence and is selected from Cl or Br and X 2 is as defined above;

(b) reacting compound 137 with a phosphite compound of the structure of Formula A.

wherein R 9 is selected from alkyl, aryl, heteroaryl, and arylalkyl groups having 1 to 10 carbon atoms, to produce compound 138,

wherein R 9 is as defined above;

(c) treating compound 138 with HX 3 , where X 3 is selected from Cl and Br, to precipitate the corresponding hydrohalide salt of Formula 138A,

wherein R 9 is as defined above; and

(d) reacting the hydrohalide salt from step “c” with an organometallic compound capable of displacing X 2 of Formula 138A with a 3-fluorophenyl moiety of Formula B′,

to produce compound 116.

15. The process of claim 14 wherein the organometallic compound used in step “d” is selected from the group consisting of: fluoroaryl-alkylboranes; fluoroaryl-haloboranes; and fluoroaryl-zinc, -aluminium, -magnesium, and -tin reagents.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2020
From: ARALEZ PHARMACEUTICALS TRADING DAC
To: TOPROL ACQUISITION LLC
Reel/Frame 054027/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2020
From: TOPROL ACQUISITION LLC
To: XSPIRE PHARMA, LLC
Reel/Frame 053731/0376 →
RECEIVING PARTY/ASSIGNEE ADDRESS CHANGE FOR ASSIGNMENT RECORDED AT REEL/FRAME 039767/0695 Recorded Aug 31, 2018
From: MERCK SHARP & DOHME CORP.
To: ARALEZ PHARMACEUTICALS TRADING DAC
Reel/Frame 046989/0669 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY PREVIOUSLY RECORDED AT REEL: 046696 FRAME: 0772. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 30, 2018
From: ARALEZ PHARMACEUTICALS TRADING DESIGNATED ACTIVITY COMPANY
To: DEERFIELD MANAGEMENT COMPANY, L.P., AS ADMINISTRATIVE AGENT
Reel/Frame 046988/0741 →
SECURITY INTEREST Recorded Aug 24, 2018
From: ARALEZ PHARMACEUTICAL TRADING DAC
To: DEERFIELD MANAGEMENT COMPANY, L.P., AS ADMINISTRATIVE AGENT
Reel/Frame 046696/0772 →
SECURITY INTEREST Recorded Sep 29, 2016
From: ARALEZ PHARMACEUTICALS TRADING DAC
To: DEERFIELD PRIVATE DESIGN FUND III, L.P.; DEERFIELD INTERNATIONAL MASTER FUND, L.P.; DEERFIELD PARTNERS, L.P.
Reel/Frame 039892/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2016
From: MERCK SHARP & DOHME CORP.
To: ARALEZ PHARMACEUTICALS TRADING DAC
Reel/Frame 039767/0695 →
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →